UNSPSC 51392407: Arbutamine hydrochloride

This classification denotes a beta-adrenergic agonist with the molecular formula C18H23NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K0NF2CPJ7F, chemically known as 1,2-benzenediol, 4-(1-hydroxy-2-((4-(4-hydroxyphenyl)butyl)amino)ethyl)-, (r)-, hydrochloride but more generally known as arbutamine hydrochloride, which bears US NIH Compound Identifier 166551. The base compound, Arbutamine, most often comes in base and hydrochloride forms.

UNSPSC 51392407 Arbutamine hydrochloride is a Commodity code covering pharmaceutical products, but the recent state and local procurement activity under this code does not align with arbutamine itself. Seminole County, Florida posted an IFB (Solicitation Number IFB60459723LAS) in June 2026 for naloxone and drug deactivation systems—medications and equipment unrelated to arbutamine hydrochloride. This mismatch suggests the code may be tagged incorrectly in the county's procurement system, or the opportunity represents a broad pharmaceutical-procurement category that encompasses multiple drug products and related health supplies. State and local governments using this code appear to be health departments and county health agencies focused on community health initiatives, substance-abuse response, and overdose-prevention programs.

Seminole County's naloxone and drug deactivation systems procurement represents the primary recent activity visible under this code. The IFB required vendors to provide 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The bid was posted June 30, 2026, with a response deadline of July 26, 2023 (a date discrepancy in the source suggests data quality issues). Vendors had to include all shipping and delivery costs, meet drug-free workplace and E-Verify compliance, and maintain workers' compensation and commercial general liability insurance. The contract carried a two-year initial term with a one-year renewal option and a three-month probationary period. FEMA funding was flagged as a potential source, introducing additional federal compliance requirements. Given the code mismatch and limited recent activity, pursuit should focus on clarifying whether opportunities under this code actually address arbutamine hydrochloride or broader pharmaceutical-supply categories before investing in response infrastructure.